Separate names with a comma.
AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder July 6, 2026...
FDA Tracker flagged Definium’s Voyage Phase 3 GAD trial as having a July 1, 2026 primary completion date for NCT06741228. FDA Tracker notes...
GW Pharmaceuticals / Epidiolex is the pathway precedent people should be studying with respect to psychedelic biotech. Jazz Pharmaceuticals...
Bipartisan Congressional Bill Would Codify Trump’s Psychedelics Order Into Law...
Raising the Bar: A Higher Standard for Mental Health Care This is the latest edition of Forward Focus, a regular feature exploring the future of...
LSD therapy biotech Definium fends off trade-secret lawsuit...
DFTX - Updated Resources and Major Recent Events and Milestones 1. The raise is a major institutional signal, not just “more cash.” Definium...
This hiring slate is bullish as a launch-readiness signal, having like a company that believes DT120 has moved from “clinical asset” to “potential...
Top 3 Health Care Stocks That May Keep You Up At Night In June...
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity...
Definium’s Phase 3 LSD Win Is Real. The Fracture It Exposed Is Bigger....
Psychedelics iPhone moment [MEDIA]
$PSIL ETF show the three biggest holdings as $DFTX $CMPS $ATAI Others will succeed too, but these three are the unicorns in the psychedelic...
Sekur Private Data Makes First Intl. Call on SekurOne - Launches SekurOne for Android and Web 06/29/2026 - 08:30 AM SekurOne iOS Voice Launch on...
